Search results
Showing 46 to 60 of 114 results for bladder cancer
High dose rate brachytherapy for carcinoma of the cervix (HTG104)
Evidence-based recommendations on high dose rate brachytherapy for carinoma of the cervix. This involves giving radiation at a high dose rate to the cervix (reducing the timeframe compared with low or medium dose rates) to treat the cancer.
View recommendations for HTG104Show all sections
Sections for HTG104
Awaiting development Reference number: GID-TA11868 Expected publication date: TBC
Evidence-based recommendations on Memokath 051 Ureter stent for ureteric obstruction.
Awaiting development Reference number: GID-TA11517 Expected publication date: TBC
Spinal metastases and metastatic spinal cord compression (QS56)
This quality standard covers diagnosis and management of spinal metastases and metastatic spinal cord compression. It describes high-quality care in priority areas for improvement.
View quality statements for QS56Show all sections
Sections for QS56
- Quality statements
- Quality statement 1: Information about recognising the symptoms of metastatic spinal cord compression
- Quality statement 2: Imaging and treatment plans for adults with suspected spinal metastases
- Quality statement 3: Imaging for adults with suspected metastatic spinal cord compression
- Quality statement 4: Coordinating investigations for adults with suspected metastatic spinal cord compression
- Quality statement 5: Coordinating care for adults with metastatic spinal cord compression
- Quality statement 6: Radiotherapy for metastatic spinal cord compression
- Quality statement 7: Supportive care and rehabilitation
This quality standard covers diagnosing and managing irritable bowel syndrome in adults. It describes high-quality care in priority areas for improvement.
Laparoscopic prostatectomy for benign prostatic obstruction (HTG176)
Evidence-based recommendations on laparoscopic prostatectomy for benign prostatic obstruction. This involves removing the prostate through small cuts in the abdomen, using a fine telescope to see inside the body (keyhole surgery).
View recommendations for HTG176Show all sections
Sections for HTG176
Durvalumab for treating metastatic urothelial bladder cancer after chemotherapy [ID1172]
Discontinued Reference number: GID-TA10394
Our centralised approach to prioritising guidance topics ensures that we produce guidance that is relevant, timely, accessible, and has demonstrable impact.
Focal therapy using high-intensity focused ultrasound for localised prostate cancer (HTG667)
Evidence-based recommendations on focal therapy using high-intensity focused ultrasound for localised prostate cancer. This involves using high-intensity focused ultrasound to heat up and destroy only the areas of the prostate with cancer (focal therapy). The aim is to destroy the cancer while reducing damage to healthy prostate tissue.
View recommendations for HTG667Show all sections
Awaiting development Reference number: GID-TA10967 Expected publication date: TBC
Signatera for detecting molecular residual disease from solid tumour cancers (MIB307)
NICE has developed a medtech innovation briefing (MIB) on Signatera for detecting molecular residual disease from solid tumour cancers .
Minimally invasive radical hysterectomy for early stage cervical cancer (HTG565)
Evidence-based recommendations on minimally invasive radical hysterectomy for early stage cervical cancer. This involves removing the uterus, cervix, upper vagina and some lymph nodes.
View recommendations for HTG565Show all sections
High-intensity focused ultrasound for prostate cancer (HTG70)
Evidence-based recommendations on high-intensity focused ultrasound for treating prostate cancer. This involves inserting a probe through the rectum that gives out a beam of ultrasound to heat and destroy the cancerous prostate tissue.
View recommendations for HTG70Show all sections
Sections for HTG70
NICE has developed a medtech innovation briefing (MIB) on the S-Cath System for suprapubic catheterisations